A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks

Human Vaccines and Immunotherapeutics

Volumn 13, Issue 2, 2017, Pages 266-270

  Shukarev, Georgi ^a   Callendret, Benoit ^b   Luhn, Kerstin ^b   Douoguih, Macaya ^b  

^a Janssen Vaccines AG   (Switzerland)

^b Janssen Research and Development   (Netherlands)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e INSERM   (France)

Author keywords

Ad26.ZEBOV MVA BN Filo; Ebola virus; heterologous prime boost; population vaccination strategy; sustained immunity; viral persistence

Indexed keywords

VIRUS GLYCOPROTEIN; EBOLA VACCINE;

BODY FLUID; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; MEMORY T LYMPHOCYTE; NONHUMAN; NOTE; VACCINATION; VESICULOVIRUS; VIRUS INFECTION; VIRUS TRANSMISSION; ZAIRE EBOLAVIRUS; CLINICAL TRIAL; DISEASE OUTBREAKS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMAN; IMMUNOLOGY; PHASE 1 CLINICAL TRIAL; TIME FACTOR;

DISEASE OUTBREAKS; EBOLA VACCINES; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; TIME FACTORS;

EID: 85010684143     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2017.1264755     Document Type: Note

References (32)

1. Pringle CR. Virus taxonomy—San Diego 1998. Arch Virol 1998; 143:1449-60; PMID:9742051; http://dx.doi.org/10.1007/s007050050389
2. Brainard J, Pond K, Hooper L, Edmunds K, Hunter P. Presence and persistence of ebola or Marburg virus in patients and survivors:a rapid systematic review. PLoS Negl Trop Dis 2016; 10:e0004475; PMID:26927697; http://dx.doi.org/10.1371/journal.pntd.0004475
3. Centres for Disease Control and Prevention. Ebola (Ebola virus disease) About Ebola Virus Disease. 2016a. http://www.cdc.gov/vhf/ebola/about.html. Last accessed:26August2016.
4. Centres for Disease Control and Prevention. Ebola (Ebola virus disease) Case counts. 2016b. https://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/. Last accessed:26August2016.
5. Chughtai AA, Barnes M, Macintyre CR. Persistence of Ebola virus in various body fluids during convalescence:evidence and implications for disease control and transmission. Epidemiol Infect 2016; 144:1652-60; PMID:26808232; http://dx.doi.org/10.1017/S0950268816000054
6. Fallah M, for the Prevail III Research Team. A cohort study of survivors of Ebola virus infection in Liberia (PREVAIL III). Abstract presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2016, February22–25, 2016, Boston, MA, USA; Abstract 74LB.
7. World Health Organization. Origins of the 2014 Ebola epidemic. January 2015 (2015a). http://www.who.int/csr/disease/ebola/one-year-report/virus-origin/en. Last accessed:26August2016.
8. Marí Saéz A, Weiss S, Nowak K, Lapeyre V, Zimmermann F, Düx A, Kühl HS, Kaba M, Regnaut S, Merkel K, et al. Investigating the zoonotic origin of the West African Ebola epidemic. EMBO Mol Med 2015; 7:17-23; http://dx.doi.org/10.15252/emmm.201404792
9. World Health, Organization. Report of the Ebola interim assessment panel. May 2015 (2015b). www.who.int/csr/resources/publications/ebola/ebola-interim-assessment/en/. Last accessed:26August2016.
10. Kamradt-Scott A. WHO's to blame? The World Health Organization and the 2014 Ebola outbreak in West Africa. Third World Quarterly 2016; 37:401-8; http://dx.doi.org/10.1080/01436597.2015.1112232
11. World Health Organization. Ebola situation report. 3 February 2016 (2016a). http://apps.who.int/ebola/current-situation/ebola-situation-report-3-february-2016. Last accessed:26August2016.
12. World Health Organization. Hundreds of contacts identified and monitored in new Ebola flare-up in Guinea. 22 March 2016 (2016b). http://www.who.int/csr/disease/ebola/guinea-flareup-update/en/. Last accessed:26August2016.
13. World Health Organization. Emergency response to Ebola flare underway in Liberia. Case investigation widens to Guinea. 04 April 2016 (2016c). http://www.who.int/csr/disease/ebola/liberia-flareups-update/en/. Last accessed:26August2016.
14. Arias A, Watson SJ, Asogun D, Tobin EA, Lu J, Phan MVT, Jah U, Wadoum REG, Meredith L, Thorne L, et al. Rapid outbreak sequencing of Ebola virus in Sierra Leone identifies transmission chains linked to sporadic cases. Vir Evol 2016; 2:vew016
15. Blackley DJ, Wiley MR, Ladner JT, Fallah M, Lo T, Gilbert ML, Gregory C, D'ambrozia J, Coulter S, Mate S, et al. Reduced evolutionary rate in reemerged Ebola virus transmission chains. Sci Adv 2016; 2:e1600378; PMID:27386513; http://dx.doi.org/10.1126/sciadv.1600378
16. Ayukekbong JA. The 2014–2015 Ebola saga:lessons for the future. J Epidemiol Community Health 2016; 70(1):1-2; PMID:26372790; http://dx.doi.org/10.1136/jech-2015-206138
17. Ledgerwood JE, DeZure AD, Stanley DA, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A, Sitar S, et al. Chimpanzee adenovirus vector Ebola vaccine–preliminary report. N Engl J Med 2015; 373:776; PMID:26287857
18. Henao-Restrapo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, et al. Lancet 2015; 386:857-86; PMID:26248676; http://dx.doi.org/10.1016/S0140-6736(15)61117-5
19. Agnandji S, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 2016; 374:1647-60; PMID:25830326; http://dx.doi.org/10.1056/NEJMoa1502924
20. Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E, Nuthall E, Voysey M, Silva-Reyes L, McElrath MJ, et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored ebola vaccines:A randomized clinical trial. JAMA 2016; 315(15):1610-23; PMID:27092831; http://dx.doi.org/10.1001/jama.2016.4218
21. Coltart CE, Johnson AM, Whitty CJ. Role of healthcare workers in early epidemic spread of Ebola:policy implications of prophylactic compared to reactive vaccination policy in outbreak prevention and control. BMC Med 2015; 13:271; PMID:26482396; http://dx.doi.org/10.1186/s12916-015-0477-2
22. Kucharski AJ, Eggo RM, Watson CH, Camacho A, Funk S, Edmunds WJ. Effectiveness of ring vaccination as control strategy for Ebola virus disease. Emerg Infect Dis 2016; 22:105-8; PMID:26691346; http://dx.doi.org/10.3201/eid2201.151410
23. CIDRAP & Wellcome Trust. Recommendations for accelerating the development of Ebola vaccines. February 2015. Available at:http://www.cidrap.umn.edu/recommendations-accelerating-development-ebola-vaccines-0. Last accessed:26August2016.
24. World Health Organization. WHO recommendations for routine immunization–summary tables. February 2015 (2015c). http://www.who.int/immunization/policy/immunization_tables/en/. Last accessed:26August2016.
25. Lu S. Heterologous Prime-Boost Vaccination. Curr Opin Immunol 2009; 21:346-51; PMID:19500964; http://dx.doi.org/10.1016/j.coi.2009.05.016
26. Moorthy BM, Fast P, Greenwood B. Heterologous prime-boost immunisation in Ebola vaccine development, testing and licensure. Report of a WHO Consultation held on 21 November 2014, Geneva, Switzerland. http://www.who.int/immunization/research/meetings_workshops/WHO_primeboost_Ebola_21nov14_meeting_report.pdf. Last accessed 26August2016.
27. EBOVAC Projects. The Trials–EBOVAC-Salone. 2016. Available at:http://www.ebovac.org/the-trials/the-trials-phase-3/. Last accessed 26August2016.
28. United Nations. Making a difference:The global Ebola response outlook 2015. https://ebolaresponse.un.org/sites/default/files/ebolaoutlook_full.pdf. Last accessed 26August2016.
29. Vinson JE, Drake JM, Rohani P, Park AW. The potential for sexual transmission to compromise control of Ebola virus outbreaks. Biol Lett 2016; 12:20151079; PMID:27277951; http://dx.doi.org/10.1098/rsbl.2015.1079
30. World Health Organization. WHO Ebola vaccine target product profile. 05 January 2016 (2016d). http://www.who.int/immunization/research/target-product-profile/ebolavaccine/en/. Last accessed:26August2016.
31. MacDermott NE, Bausch DG. Virus persistence and recrudescence after Ebola virus disease:what are the risks of healthcare workers? J Hosp Infect 2016; 94(2):113-115; PMID:27499080; http://dx.doi.org/10.1016/j.jhin.2016.07.004
32. Osterholm M, Moore K, Ostrowsky J, Kimball-Baker K, Farrar J, Wellcome Trust-CIDRAP Ebola Vaccine Team B. The Ebola Vaccine Team B:a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats. Lancet Infect Dis 2016; 16:e1-9; PMID:26526664; http://dx.doi.org/10.1016/S1473-3099(15)00416-8